Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Verastem Slashes Staff After Mesothelioma Failure

This article was originally published in Scrip

Executive Summary

Verastem Inc. is slashing its head count by 50%, or 20 employees, as the company continues to regroup after lead drug candidate VS-6063 failed to show an efficacy benefit for mesothelioma patients at an interim analysis in a Phase II clinical trial.

You may also be interested in...



Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie

Duvelisib, licensed from Infinity in 2016, reduces risk of disease progression or death compared to Arzerra in a Phase III study in refractory CLL/SLL. Verastem hopes to file an NDA during the first half of 2018.

Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies

Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.

SPAC Mergers Are Viable Funding Tools, But The Test Is Yet To Come

Dozens of health care-focused special purpose acquisition corporations have gone public during the past two years but many biopharma firms that have merged with SPACs have not performed well to date, raising the question of how long the SPAC boom will last.

Topics

UsernamePublicRestriction

Register

SC030004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel